Crohn's disease
CD · Immunology · 5 drugs · 5 indications
Competitive Landscape (5 drugs)
| Drug | Company | Mechanism | Modality | Route | Stage |
|---|
| Tulisokibart | MRK | TL1A inhibitor | Biologic | IV | PHASE3 |
| Cimzia | UCB | TNF inhibitor | Antibody | SC | APPROVED |
| Entyvio | — | Gut-selective α4β7 integrin inhibitor | Antibody | IV | APPROVED |
| Skyrizi | ABBV | IL-23 inhibitor | Biologic | IV/SC | APPROVED |
| Rinvoq | ABBV | JAK inhibitor | Small molecule | ORAL | APPROVED |
Indications (5)
Moderate-severe Crohn's disease
Upcoming Catalysts
Rinvoq - Vitiligo - FDA ApprovalREGULATORY
ABBV2026
Skyrizi - Psoriasis - H2H vs DeucravacitinibCLINICAL
ABBV2026
Rinvoq - GCA - FDA ApprovalREGULATORY
ABBV2026
Rinvoq - Alopecia Areata - Ph3 - Data (UP-AA)CLINICAL
ABBV2026
Rinvoq - HS - Ph3 - DataCLINICAL
ABBV2026
Rinvoq - SLE - Ph3 - DataCLINICAL
ABBV2026
Tulisokibart - UC - Ph3 - Topline (ATLAS-UC)CLINICAL
MRKNov 2026
Data from Supabase · Updated 2026-03-24